MN-18

MN-18 is a synthetic cannabinoid that is structurally related to another synthetic cannabinoid, NNE1. It was first identified in Belgium in January 2016 and has been sold online as a designer drug. It is unclear where MN-18 originally came from. It is often found in products marketed as herbal incense or synthetic cannabis.

Chemistry[edit | edit source]

MN-18 is a derivative of NNE1, which is itself a derivative of JWH-018. The only structural difference between MN-18 and NNE1 is the addition of a methyl group. This makes MN-18 a homologue of NNE1. The full chemical name of MN-18 is naphthalen-1-yl(4-pentyl-1H-indazol-3-yl)methanone.

Pharmacology[edit | edit source]

The pharmacology of MN-18 is not well understood. However, it is known to act as a full agonist at the CB1 receptor, which is the same receptor that THC, the main active ingredient in cannabis, acts on. This suggests that MN-18 may have similar effects to cannabis, although this has not been confirmed in scientific studies.

Legal status[edit | edit source]

MN-18 is illegal in many countries, including the United States, where it is classified as a Schedule I drug. It is also illegal in the United Kingdom, where it is classified as a Class B drug.

See also[edit | edit source]

MN-18 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.